Browsing by Author "Nyabayo Maniga, Josephat"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Impact of Intervention Practices on Malaria Treatment Outcomes Among Patients in Bushenyi District, Uganda
    (Research Square, 2021) Nyabayo Maniga, Josephat; Kalenzi Atuhaire, David; Mugasa, Claire Mack
    Malaria remains a major vector borne disease causing both mortalities and morbidities in the world. Uganda as a country has currently scaled out major campaigns to reduce and eliminate the disease using different interventions. However, there is no clear data on the impact of such interventions on malaria treatment outcomes. Therefore, this study was aimed at assessing the impact of malaria intervention practices on Artemether- Lumefantrine (AL) treatment outcomes among the residents of Bushenyi district, Uganda, a high intensity malaria transmission area. Methods This was a descriptive cross-sectional study carried out among 184 study participants for a period of one year (August 2017 to August 2018) in four selected health centers in Bushenyi district, Uganda. The investigative methods used included a researcher administered questionnaire, laboratory and clinical evaluations of participants. Data analysis was done by using statistical package for social sciences (SPSS version 10 windows) for descriptive statistics. Results Statistically significant factors for treatment outcome at p ≤0.05 were; practicing indoor residual spraying (IRS) at home (𝑃 = 0.001; CI), source of prescription (𝑃 = 0.018; CI), finishing dosage (𝑃 = 0.006; CI), frequency of malaria infection (𝑃 = 0.028; CI), Frequency of antimalaria usage (𝑃 = 0.042; CI) and sleeping under insecticide treated nets (ITNs) (𝑃 = 0.039; CI) respectively. Conclusions IRS and ITNs were found to be the major intervention practice of malaria reduction after treatment with ACTs.
  • Thumbnail Image
    Item
    Plasmodium falciparum Malaria Clinical and Parasitological Outcomes after In-vivo Artemether- Lumefantrine (AL) Treatment at Bushenyi District Uganda
    (International Journal of Tropical Disease & Health, 2018) Nyabayo Maniga, Josephat; Aliero, Adamu Almustapha; Ntulume, Ibrahim; Okech, Matilda Angela; Claire Mack, Mugasa
    The aim of this study was to determine the Plasmodium falciparum malaria clinical and parasitological outcomes after in-vivo Artemether-Lumefantrine (AL) treatment at Bushenyi District Uganda. Study Design: This was a one-arm prospective longitudinal health point survey. Place and Duration: This study was carried out in Bushenyi District Uganda as from May 2017 to August 2017 for a period of four months at the selected four health centers. Methodology: A cohort of 283 human participants who had been confirmed of Plasmodium falciparum malaria was followed for a period of 28 days after treatment with Artemether-Lumefatrine (AL) drug. The follow up was done at fixed check up visits i.e. day 0, 1, 2, 3, 7, 14, 28. Parasitological and clinical evaluations were done at each subsequent follow up days. Consequently they were requested to fill a questionnaire which had aspects of malaria infection. Results: Out of the 283 participants recruited to this study 194 (68.6%) participants completed the follow up schedules while 89 (31.4%) were withdrawn from the study. There was adequate clinical and parasitological response (ACPR) among 53(27.3%) participants. There was late parasitological failure (LPF) among 43 (22.2%) participants. There was late clinical failure (LCF) among 23(11.9%) participants and there was early treatment failure (ETF) among 75 (38.7%) participants Conclusion: There was suspected Artemether- Lumefantrine (AL) poor response to Plasmodium falciparum malaria in the study area after 8 years of introduction to Uganda as a drug of choice for treatment of uncomplicated malaria. Those aged 5 years and below were 2.28 times more likely to present LCF as a clinical treatment outcome compared to other age groups when other factors were held constant. Molecular confirmation of the suspected resistance needs to be conducted in the collected Plasmodium falciparum isolates.